Latest news with #DISCOVER
Yahoo
11-06-2025
- Health
- Yahoo
Regeneron and Sanofi's dupilumab shows promise in AD trial
Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent(dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in adolescents and adults with skin of colour. The data were presented at the 2025 Revolutionizing Atopic Dermatitis Conference. In the study, 120 subjects with AD and skin of colour received Dupixent biweekly. At the 24-week mark, 76% of them achieved a ≥75% improvement in overall disease severity, with some noticing benefits as early as two weeks. Additionally, 53% of patients saw a reduction in itch, and there was a 53% decrease in post-inflammatory hyperpigmentation from baseline. The trial's safety outcomes aligned with Dupixent's established safety profile in dermatological uses. Subjects in the DISCOVER trial, aged 12 years and above, were treated with Dupixent monotherapy based on weight. The primary endpoint was achieving a minimum of a 75% improvement on the Eczema Area and Severity Index (EASI-75) at 24 weeks. Secondary and additional endpoints are the proportion of subjects achieving ≥4-point improvement on the Peak-Pruritus Numerical Rating Scale (PP-NRS). The skin of colour was defined as per Fitzpatrick skin types IV-VI. AD, a chronic skin condition characterised by type 2 inflammation, can be particularly severe in individuals with skin of colour, often leading to more pronounced symptoms and skin lesions. Invented using Regeneron's VelocImmune technology, Dupixent is a monoclonal antibody that blocks the signalling of interleukin-4 and interleukin-13 pathways without being an immunosuppressant. It is a collaborative effort between Sanofi and Regeneron. The companies recently reported that the Phase III AERIFY-1 trial of itepekimab in former smokers who have inadequately controlled chronic obstructive pulmonary disease (COPD), met the primary goal. "Regeneron and Sanofi's dupilumab shows promise in AD trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Insider
08-06-2025
- Business
- Business Insider
Regeneron, Sanofi presents results from DISCOVER Phase 4 trial of Dupixent
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones. The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones. The data were shared in an oral presentation at the 2025 Revolutionizing Atopic Dermatitis, RAD, Conference. In the trial, 120 patients with atopic dermatitis and skin of color were treated with Dupixent every two weeks using a weight-based dosing regimen. At 24 weeks: 76% achieved a greater than or equal to75% improvement in overall disease severity, the primary endpoint. Improvements were seen by some patients as early as two weeks. 53% achieved clinically meaningful improvement in itch. Improvements were seen by some patients as early as two weeks. Patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, dropping from 5.1 points to 2.4 points. 18% were very or extremely bothered by dry skin vs. 78% at baseline, based on patient reporting. Confident Investing Starts Here:
